News Sentiment

ZBIO sentiment intelligence

Zenas BioPharma, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 72 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 28.74 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+5.5% over one week, +45.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO)

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 5.5% Price confirming higher
Trend fit Trend inactive 45.2% over four weeks
Fair value 58.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 47
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 8
Market source 7
The National Law Review 6
TradingKey 4
GlobeNewswire 4
simplywall.st 3
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 18
Regulatory and legal 8
Balance sheet 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 72
Sahm Direct company coverage

Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey

Zenas BioPharma (ZBIO) has been reclassified into several Russell growth indexes after significant share price momentum. Despite this, the article questions its current valuation, noting its price-to-book ratio of 5.2x is significantly higher than peers and the industry average,

Tone
Negative 29/100
Event
Market update
Published
08 Jul 2026 11:39
Source
Sahm
Stock Titan Direct company coverage

If You Invested $1,000 in Zenas BioPharma Inc. (ZBIO)

This article analyzes the historical performance of Zenas BioPharma Inc. (ZBIO) stock, demonstrating potential returns on $1,000 and $10,000 investments over different periods. It also provides a detailed overview of Zenas BioPharma, a clinical-stage biopharmaceutical company foc

Tone
Positive 65/100
Event
Market update
Published
06 Jul 2026 12:12
Source
Stock Titan
Finviz Direct company coverage

ZBIO - Zenas Biopharma Inc Earnings

This article provides a detailed financial overview of Zenas Biopharma Inc. (ZBIO), including its market cap, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's recent stock close, percentage change, and future

Tone
Negative 39/100
Event
Earnings
Published
02 Jul 2026 21:39
Source
Finviz
The National Law Review Direct company coverage

Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders

A securities class action lawsuit has been filed against Zenas BioPharma, Inc. (NASDAQ:ZBIO) on behalf of investors who purchased shares related to its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the amount of time it could fund operations with exi

Tone
Negative 9/100
Event
Regulatory and legal
Published
01 Jul 2026 21:09
Source
The National Law Review
The National Law Review Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is urging shareholders who purchased Zenas BioPharma (NASDAQ:ZBIO) securities before September 13, 2024, and still hold them, to inquire about a potential securities investigation. The firm is investigating whether Zenas BioPharma and its office

Tone
Negative 29/100
Event
Regulatory and legal
Published
30 Jun 2026 12:41
Source
The National Law Review
The National Law Review Direct company coverage

Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class Action - Contact Levi & Korsinsky

Levi & Korsinsky, LLP announced a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities following its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the duration its existing cash and IPO proceeds co

Tone
Negative 9/100
Event
Regulatory and legal
Published
29 Jun 2026 22:11
Source
The National Law Review
www.marketscreener.com Direct company coverage

Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark

Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 2500 Growth Benchmark. This news highlights several recent changes for the company within various Russell indices, including additions to Russell 2000 Growth and Russell Microcap Growth, while being dropped from

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 16:06
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark

Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 3000E Growth Benchmark, as announced on June 29, 2026. This inclusion reflects recent adjustments to various Russell indices, with Zenas BioPharma also being added to the Russell 2500 Growth and Russell 2000 Gro

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 05:08
Source
marketscreener.com
Simply Wall Street Direct company coverage

Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story?

Zenas BioPharma (ZBIO) has transitioned from value to growth classifications in several Russell indices, including the Russell 2000 Growth, which could amplify trading around news due to increased exposure to style and index funds. While this shift primarily affects ownership rat

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:10
Source
Simply Wall Street
The National Law Review Direct company coverage

Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities prior to September 13, 2024, and still hold them. The investigation seeks to determine if the company and its officers engaged

Tone
Negative 9/100
Event
Regulatory and legal
Published
28 Jun 2026 16:09
Source
The National Law Review
The National Law Review Direct company coverage

Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025

Levi & Korsinsky, LLP is inviting investors who suffered losses in Zenas BioPharma, Inc. (ZBIO) to join a class action lawsuit. The lawsuit alleges that Zenas BioPharma made false and misleading statements regarding its ability to fund operations following its September 2024 IPO.

Tone
Negative 20/100
Event
Regulatory and legal
Published
27 Jun 2026 19:09
Source
The National Law Review
The National Law Review Direct company coverage

Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors

Levi & Korsinsky has notified investors of Zenas BioPharma, Inc. (ZBIO) about a securities lawsuit, with a lead plaintiff deadline of June 16, 2025. The lawsuit alleges that Zenas BioPharma made false statements regarding its ability to fund operations relying on existing cash an

Tone
Negative 23/100
Event
Regulatory and legal
Published
27 Jun 2026 14:09
Source
The National Law Review
TMX Newsfile Direct company coverage

ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm -

Rosen Law Firm is notifying investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) who purchased securities pursuant to the company's September 2024 IPO that the lead plaintiff deadline for a securities class action is June 16, 2025. The lawsuit alleges that the Registration Statement

Tone
Negative 18/100
Event
Regulatory and legal
Published
27 Jun 2026 06:40
Source
TMX Newsfile
TradingView Direct company coverage

Enterprise value to EBITDA forward of Zenas BioPharma, Inc. – BOATS:ZBIO

This article briefly displays the "Enterprise value to EBITDA forward" metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It shows that the market for ZBIO was closed with no trades recorded at the time of viewing. The content primarily focuses on presenting thi

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Zenas BioPharma, Inc. – NASDAQ:ZBIO

This article provides the enterprise value to revenue forward for Zenas BioPharma, Inc. (NASDAQ: ZBIO) as presented on TradingView. It indicates that the market is closed and no trades have occurred. The information is sourced from various financial data providers like ICE Data S

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Zenas BioPharma, Inc. – BOATS:ZBIO

This article provides the "Price to sales forward" value for Zenas BioPharma, Inc. (ZBIO) on the Blue Ocean Alternative Trade System. It specifies the period, value, and change, noting that the data is provided by ICE Data Services and FactSet. The data indicates that the market

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Zenas BioPharma, Inc. – BOATS:ZBIO

This article provides access to the 'Price to book forward' financial metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It highlights that the market was closed at the time of viewing, indicating no recent trades for the company. The content is primarily a data

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:11
Source
TradingView
TradingKey Direct company coverage

Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Zenas Biopharma Inc (ZBIO), noting its current valuation score of 6.82, which ranks 275 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.22, significantly below its recent high.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 09:41
Source
TradingKey
Stock Titan Direct company coverage

Zenas BioPharma grants new hires 178,075 equity awards

Zenas BioPharma (ZBIO) announced the grant of inducement equity awards totaling 178,075 shares to newly hired employees on June 15, 2026, including 100,000 non-qualified stock options with an exercise price of $18.71 and 78,075 Restricted Stock Units (RSUs). These awards, granted

Tone
Positive 63/100
Event
Market update
Published
21 Jun 2026 11:41
Source
Stock Titan
TradingKey Direct company coverage

Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Zenas Biopharma Inc.'s (ZBIO) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no historical stock split data available. The piece presents current stock perform

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 17:39
Source
TradingKey
Stock Titan Direct company coverage

Zenas BioPharma (ZBIO) director awarded 18,500 options at $18.71

Zenas BioPharma (ZBIO) director James P. Boylan was granted 18,500 stock options at an exercise price of $18.71 per share as compensation. These options will vest 100% on June 15, 2027, provided Boylan remains in service, and are set to expire on June 15, 2036. The filing indicat

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 14:40
Source
Stock Titan
TradingKey Direct company coverage

Zenas Biopharma Inc (ZBIO) Institutional Confidence

Zenas Biopharma Inc (ZBIO) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.12%, marking a 20.91% decrease quarter-over-quarter. Bill Nygren | OAKMX is the la

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:10
Source
TradingKey
Stock Titan Direct company coverage

Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff

Zenas BioPharma (ZBIO) has granted its director, John J. Orloff, 18,500 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 100% on June 15, 2027, contingent on his continued service. This transaction is classified as a grant

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:39
Source
Stock Titan
Stock Titan Direct company coverage

Zenas BioPharma (ZBIO) awards 150,000 stock options to officer

Zenas BioPharma, Inc. has granted 150,000 stock options to officer Lisa von Moltke. These options have an exercise price of $18.71 per share and will expire on June 15, 2036. The vesting schedule indicates that 25% of the options will vest on June 15, 2027, with the remaining 75%

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:39
Source
Stock Titan